A phase 3 trial of bevacizumab in ovarian cancer
Timothy J. Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A. Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S. Carey, Philip Beale, Andreś Cervantes, Christian Kurzeder, Andreas Du Bois, Jalid Sehouli, Rainer Kimmig, Anne Staḧle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Fred́eŕic Selle, Mansoor R. Mirza
*Korrespondierende/r Autor/-in für diese Arbeit
- St. James's Institute of Oncology
- St James's University Hospital
- Medical Research Council
- Städtischen Klinikum Solingen
- Klinik für Gynäkologie und Geburtshilfe
- University College London
- Universität Paris V
- University of Oslo
- Department of Obstetrics and Gynecology
- University of British Columbia
- Australia New Zealand Gynaecological Oncology Group
- Department of Radiation Oncology
- University of Valencia
- Universität Ulm
- Dr. Horst Schmidt Klinik GmbH
- Charite - Universitatsmedizin Berlin
- Universität Duisburg-Essen
- Formerly St. Vincentius Kliniken
- St. Luke's Cancer Center
- Royal Brompton and Harefield NHS Foundation Trust
- Centre for Genomics and Experimental Medicine
- University of Edinburgh
- Centre Catherine de Sienne
- Hopital Tenon
- Department of Oncology
- Copenhagen University Hospital Rigshospitalet
- Women's Clinic
- University of Helsinki
- Department of Obstetrics and Gynecology
- Laval University
- Leeds Institute of Molecular Medicine
- Cambridge Cancer Trials Center
- University of Cambridge
- Princess Margaret Cancer Centre
2017
!!Link opens in a new tab
Zitate (Scopus)